No Data
No Data
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-2129 tablets obtained the drug clinical trial approval notification.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced on September 23 that its subsidiaries Shanghai Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceuticals Co., Ltd. have received the approval letter for the clinical trial of HRS-2129 tablets issued by the National Medical Products Administration, and will conduct clinical trials in the near future. The HRS-2129 tablets are intended for the treatment of acute and chronic pain. Currently, there are no similar products approved for marketing domestically or internationally. As of now, the cumulative research and development expenses for the HRS-2129 tablet project have reached approximately 29.83 million yuan.
Hengrui Medicine's Ruilafupu-α Injection Receives Marketing Authorization in China; Shares Drop 5%
Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
China Accepts Hengrui Medicine Unit's Marketing Application for Cancer Drug
Jiangsu Hengrui Pharmaceuticals (600276.SH): The application for marketing authorization of Rucanezumab for injection has been accepted.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biomedical Co., Ltd., has received the "Acceptance Notice" issued by the National Medical Products Administration for the marketing authorization application of its pharmaceutical product, Injection of Ruirang Qutuozhudankan (SHR-A1811). The application has been accepted by the National Medical Products Administration and the product has recently been included in the priority review process. Injection of SHR-A1811 can bind and internalize with tumor cells expressing HER2, release toxins through proteinase cleavage in tumor cell lysosomes, induce cell cycle arrest, and induce tumor cell apoptosis.
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
No Data
No Data